key: cord-0828467-zale8c2n
authors: Loader, Jordan; Lampa, Erik; Gustafsson, Stefan; Cars, Thomas; Sundström, Johan
title: Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
date: 2021-07-29
journal: J Am Heart Assoc
DOI: 10.1161/jaha.120.021154
sha: eec5d5dde782e928ee75d231db4fb694dcd1fc21
doc_id: 828467
cord_uid: zale8c2n

BACKGROUND: Considering the widespread risk of collider bias and confounding by indication in previous research, the associations between renin‐angiotensin aldosterone system (RAAS) inhibitor use and COVID‐19 remain unknown. Accordingly, this study tested the hypothesis that RAAS inhibitors influence the summation effect of COVID‐19 and its progression to severe outcomes. METHODS AND RESULTS: This nationwide cohort study compared all residents of Sweden, without prior cardiovascular disease, in monotherapy (as of January 1, 2020) with a RAAS inhibitor to those using a calcium channel blocker or a thiazide diuretic. Comparative cohorts were balanced using machine‐learning‐derived propensity score methods. Of 165 355 people in the analysis (51% women), 367 were hospitalized or died with COVID‐19 (246 using a RAAS inhibitor versus 121 using a calcium channel blocker or thiazide diuretic; Cox proportional hazard ratio [HR], 0.97; 95% CI, 0.74–1.27). When each outcome was assessed separately, 335 people were hospitalized with COVID‐19 (HR, 0.92; 95% CI, 0.70–1.22), and 64 died with COVID‐19 (HR, 1.22; 95% CI, 0.68–2.19). The severity of COVID‐19 outcomes did not differ between those using a RAAS inhibitor and those using a calcium channel blocker or thiazide diuretic (ordered logistic regression odds ratio, 1.01; 95% CI, 0.89–1.14). CONCLUSIONS: Despite potential limitations, this study is among the best available evidence that RAAS inhibitor use in primary prevention does not increase the risk of severe COVID‐19 outcomes; presenting strong data from which scientists and policy makers alike can base, with greater confidence, their current position on the safety of using RAAS inhibitors during the COVID‐19 pandemic.

S ARS-CoV-2 gains entry into its target cells via angiotensin-converting enzyme (ACE) 2. 1 Reninangiotensin aldosterone system (RAAS) inhibitors, such as ACE inhibitors and angiotensin II type-I receptor blockers (ARBs), may upregulate the expression of ACE2, 2-4 establishing a basis for the hypothesis that their use may increase the risk of a SARS-CoV-2 infection. 2 As of February 2021, at least 118 studies have attempted to test variants of this hypothesis. However, nearly all of them have assessed the associations between RAAS inhibitor use and COVID-19 outcomes exclusively in people with a confirmed SARS-CoV-2 infection, mainly in those hospitalized with COVID-19, introducing a high risk of collider bias. 124 Collider bias creates a spurious within-sample association between 2 variables (eg, in the context of this study: frailty caused by cardiovascular disease, with a high likelihood of being prescribed a RAAS inhibitor, and frailty caused by an adverse COVID-19 course) that affects the probability of being included in the sample (eg, being Loader et al Renin-Angiotensin System Inhibitors and COVID-19 hospitalized). 124 To understand if RAAS inhibitors can increase the risk of COVID-19, a primary prevention sample of yet uninfected people using RAAS inhibitors or a relevant comparator drug class must be studied, not those already impacted by the virus. 124 Considering this, the findings of those biased studies need to be treated with caution, 124 with the total effect of RAAS inhibitors on the risk of COVID-19 remaining unknown. Given that RAAS inhibitors are widely used in age groups where the incidence and case fatality of COVID-19 are disproportionally high, 125 there is an urgent need to provide definitive data about the safety of using these drugs during the ongoing COVID-19 pandemic. Accordingly, the present study tested the hypothesis that RAAS inhibitors influence the summation effect of a SARS-CoV-2 infection and its progression to severe COVID-19 outcomes.

Use of the analytical methods and data that support the findings of this study can be arranged with the corresponding author upon reasonable request.

The study was set in Sweden, where all residents have universal access to health care with a negligible copayment for healthcare visits, hospitalizations, and medications. 126 Following approval by the Swedish Ethical Review Authority (approval no. 2020-01556), the 12digit personal identity number, 127 unique to all Swedish residents, was used to link a variety of nationwide socioeconomic and health registries (classifying diagnoses using the International Classification of Diseases, Tenth Revision [ICD-10] system, 128 surgical procedures using the Nordic Medico-Statistical Committee Classification of Surgical Procedures system, 129 and filled drug prescriptions using the Anatomical Therapeutic Chemical [ATC] classification system 130 ) , whose only loss to follow-up was by emigration. The need for informed consent was waived.

A nationwide cohort study of all residents of Sweden in monotherapy with an antihypertensive drug as of January 1, 2020 was formed. To minimize confounding by indication, people using an ACE inhibitor (ATC code C09A), an ARB (ATC code C09C), a vascular selective calcium channel blocker (CCB; ATC code C08CA), or a thiazide diuretic (TZD; ATC codes C03AA or C03BA04) in monotherapy were included, because these are first-line choices in current European hypertension guidelines. 131 Among these, the group using a RAAS inhibitor (ie, an ACE inhibitor or an ARB) was compared with the group not using a RAAS inhibitor (ie, a CCB or TZD) in the primary analysis. Additionally, acknowledging that different classes of RAAS inhibitors do not share the same mechanistic actions, those using an ACE inhibitor and those using an ARB were also compared separately, in a secondary analysis, with the group using a CCB or TZD.

To further minimize confounding by disease severity, people using other blood pressure-lowering drugs (ATC codes C02CA04, C03DA, C07), combination pills including blood pressure-lowering drugs, or other cardiovascular drugs (ATC codes C01, C02D, C02K, C03C, C03X, C08D) were excluded. Additionally, people with preexisting cardiovascular and kidney diseases (ICD-10 codes I20, I21, I22, I24, I25.2, Z95.1,  Z95.5, I60, I61, I62, I63.0-I63.5, I63.8-I63.9, I64, I65,  I66, I69 

What Is New?

• In contrast to previous studies that have evaluated the associations between renin-angiotensin aldosterone system inhibitor use and COVID-19 outcomes, this study limits the influence of collider, indication, and confounding biases to provide the best available evidence that the use of renin-angiotensin aldosterone system inhibitors in primary prevention is not associated with COVID-19 outcomes.

What Are the Clinical Implications?

• Previously, scientists and policy makers alike were basing their current position regarding the safety of using renin-angiotensin aldosterone system inhibitors during the COVID-19 pandemic on data where the associations between renin-angiotensin aldosterone system inhibitor use and COVID-19 outcomes could be highly distorted by several types of bias. • This study provides data where those biases have been limited, fortunately supporting advice from the authorities that antihypertensive therapies should not be altered due to of the COVID-19 pandemic. 

Participants were followed in the registries from January 1, 2020 until June 23, 2020 covering the first wave of the COVID-19 pandemic in Sweden, in which around 100 to 800 new cases were recorded each day for the majority of the follow-up period, before infection rates peaked at around 1000 to 1500 cases per day in June 2020. 132 The primary outcome was defined as hospitalization and/or death with COVID-19 (ICD-10 code U07. 

Associations between exposures and the outcomes were analyzed using an intention-to-treat approach (ie, exposure groups were defined once, January 1, 2020) and an as-treated approach. Patients were considered to have stopped or changed their RAAS inhibitor therapy if they did not refill their prescription within 120 days of their previous refill. Subsequently, in the as-treated model, those patients were censored from the analyses. Bias-minimized models investigating total effects were identified using the directed acyclic graphs approach ( Figure S1 ), considering subject matter knowledge and all factors listed in the Summary of Product Characteristics for the most commonly used of the studied drugs (Table S1 ). Potential confounding was handled by weighting patients on a propensity score and by multivariable adjustment.

The propensity score was estimated using gradientboosted classification and regression trees to determine the probability of being prescribed a RAAS inhibitor or not. More information about the use of gradient-boosted classification and regression trees can be found in Data S1. The resulting propensity score was used to calculate an inverse probability of treatment weight for each individual:

where Z i is a binary indicator taking the value 1 if individual i was treated with a RAAS inhibitor and 0 otherwise, and where p i is the propensity score for individual i.

The associations between the use of RAAS inhibitors and the COVID-19 outcomes during the 6-month follow-up period were assessed in the primary analysis using Cox models weighted with this inverse probability weight, further adjusting for age, sex, income, country of birth, use of drugs affecting the immune system, diabetes mellitus, antidiabetic drug use, renal disease, hepatic disease, neoplasms, and previous RAAS inhibitor use. Proportionality of the hazards was assessed by visually examining the smoothed association of the scaled Schoenfeld residuals with time. The Aalen-Johansen estimate of the cumulative incidence function was also presented. This was repeated in the secondary analysis to evaluate the relationships between COVID-19 outcomes and the use of an ACE inhibitor or an ARB, separately.

Associations between RAAS inhibitor use and an ordinal variable indicating the severity of the outcome at the end of the 6-month follow-up period were analyzed using ordered logistic regression, using the same weights and adjustments as above.

The balance of the cohorts was assessed using the standardized mean difference between the groups, and with a falsification outcome of mortality by causes unrelated to COVID-19, which is not supposed to differ between the groups. 133 All analyses were made using R version 4.0.0 and the twang and survival add-on packages (R Foundation for Statistical Computing, Vienna, Austria). [134] [135] [136] 

Of the 1 997 479 residents of Sweden with an active blood pressure-lowering drug prescription as of January 1, 2020, there were 165 355 people who met the inclusion criteria of this study and were eligible for inclusion in the primary analysis. After removal of missing values in the adjusted variables and nonoverlapping weights, the final sample sizes included in the regressions for the primary and secondary analyses were 164 611 and 164 655, respectively ( Figure 1 ). Of those people included in the primary analysis, 115 684 were on monotherapy with a RAAS inhibitor, and 48 927 were on monotherapy with a CCB or a TZD. In the secondary analysis, 47 998 people were on monotherapy with an ACE inhibitor, 68 239 with an ARB, and 48 418 with a CCB or TZD. The characteristics of the cohort in the primary analysis is detailed in Table 1 . Characteristics of the cohort in the secondary analysis are detailed in Tables S2 and S3. Excellent balance between the weighted study groups was achieved; the standardized mean difference for all variables was near 0, and the hazard ratio for the association of RAAS Focusing on the primary analysis, 228 people using a RAAS inhibitor had been hospitalized with COVID-19, 30 had been admitted to an intensive care unit with COVID-19, 324 had died from causes unrelated to COVID-19, and 35 had died with COVID-19 at the end of the 6-month follow-up period. Of those on monotherapy with a CCB or TZD, 107 people were hospitalized with COVID-19, 15 were admitted to an intensive care unit with COVID-19, 229 died from causes unrelated to COVID-19, and 29 died with COVID-19.

There were no statistical differences in the rates of all COVID-19 outcomes between those using a RAAS inhibitor and those using a CCB or TZD (Table 2 and Figure 2 ). Additionally, there was no difference in the severity of the COVID-19 outcomes between these groups (odds ratio, 1.01; 95% CI, 0.89-1.14, from an ordered logistic regression). There were also no statistical differences in the rates of all COVID-19 outcomes when those using an ACE inhibitor and those using an ARB were compared separately to those using a CCB or TZD (Table 3 ). These findings did not change when using either an intention-to-treat or as-tread approach. Hazard ratios did not vary with adjustment (Table S4) . Although the proportionality test indicated potentially nonproportional hazards, the plot of the smoothed association of the scaled Schoenfeld residuals with time revealed little ( Figure S2 ).

In this nationwide cohort study of initially uninfected people, there is no evidence to support that RAAS inhibitor use increases the risk of severe COVID-19 outcomes including hospitalization, admission to an intensive care unit, or death.

Of the 118 previous studies of RAAS inhibition and COVID-19 associations, 5-123 at least 102 were restricted to patients who were tested for/tested positive for a SARS-CoV-2 infection or who had been hospitalized Unweighted and weighted characteristics of the study groups included in the primary analysis, composed of all Swedish residents using an antihypertensive drug in monotherapy as of January 1, 2020. ACE indicates angiotensin-converting enzyme; ARB, angiotensin II type-I receptor blocker; CCB, calcium channel blocker; IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drug; RAAS, renin-angiotensin aldosterone system; SEK, Swedish Kronor (currency of Sweden: 8.5 SEK=1.0 USD); SMD, standardized mean difference; and TZD, thiazide diuretic.

Renin-Angiotensin System Inhibitors and COVID-19 because of COVID-19. Such inclusion strategies produce samples that are not representative of the general population and carry a high risk of collider bias, thus distorting any true associations between the use of RAAS inhibitors and the incidence of COVID-19

outcomes. 124 Unfortunately, even the more influential studies published to date suffer from this bias. 84, 95 The most comprehensive overview of this methodological problem stresses an urgent need for COVID-19 studies that use representative population samples and Figure 2 . The Aalen-Johansen estimate of the cumulative incidence function for death unrelated to COVID-19 and for a combination of hospitalization or death with COVID-19, in people on monotherapy with a renin-angiotensin aldosterone system (RAAS) inhibitor and those on monotherapy with either a calcium channel blocker (CCB) or a thiazide diuretic (TZD). Swedish residents on antihypertensive monotherapy with a RAAS inhibitor were compared with those on monotherapy with either a CCB or a TZD, in both intention-to-treat and as-treated models. CCB indicates calcium channel blocker; HR, inverse probability of treatment-weighted and multivariate-adjusted Cox proportional hazard ratio; RAAS, renin-angiotensin aldosterone system; and TZD, thiazide diuretic. thus avoid collider bias to provide reliable evidence. 124 Results from biased studies should be treated with caution by scientists and policy makers alike. 124 Four case-control studies and 10 cohort studies provided stronger study designs than most of the other RAAS inhibitor-COVID-19 research, but each study included people with prior cardiovascular and/or renal disease, which renders them highly susceptible to confounding by indication, the main pitfall in comparative effectiveness and drug-safety studies. Considering the methodological limitations in previous studies, as well as the burden that a potential inaccurate conclusion could have on patients and healthcare systems worldwide, it was warranted that the potential associations between RAAS inhibitor use and the summation effect of SARS-CoV-2 infection and the progression to severe COVID-19 outcomes be studied further and settled.

Accordingly, Semenzato et al recognized the methodological limitations in the previous research, providing the strongest study design to date by limiting the potential for collider, indication, and confounding biases. 102 In a nationwide cohort that identified patients in France being treated for uncomplicated hypertension, they found that long-term use of an ACE inhibitor or ARB may lower COVID-19 risk when compared with those using a CCB. 102 This present study addresses a major limitation of that research, extending upon it by including an as-treated analysis. Given the similarities in study design and the event rates, it is not entirely clear why the associations between RAAS inhibitor use and COVID-19 outcomes differ from the study by Semenzato et al 102 to this present research. Potentially, the difference in the effect may be simply explained by how France and Sweden have managed the COVID-19 pandemic, with approaches that varied greatly between the 2 countries (eg, nationwide lockdowns versus no lockdowns, respectively). Nevertheless, each study provides strong data that do not indicate a harmful interaction between RAAS inhibitor use and COVID-19.

The initial doubt cast over the safety of using RAAS inhibitors was driven by the finding that SARS-CoV-2 gains entry to human cells by binding its viral spike protein to ACE2. 1,2 In brief, it was hypothesized that RAAS inhibitors could increase one's susceptibility to a SARS-CoV-2 infection, as well as potentiate a more severe disease course, by increasing the expression of ACE2 on the surface of the cell. 2 Potential protective effects of RAAS inhibition have also been proposed. RAAS inhibition may potentiate the lung protective function of ACE2. 137 Given that either of these potential effects, protective or harmful, would affect the probability of infection and the probability of symptomatic disease, the most relevant population for studying the totality of the safety of RAAS inhibition should Swedish residents on antihypertensive monotherapy with an ACE inhibitor or an ARB were compared with those on monotherapy with either a CCB or TZD, in both intention-to-treat and as-treated models. ACE indicates angiotensin-converting enzyme; ARB, angiotensin II type-I receptor blocker; CCB, calcium channel blocker; HR, inverse probability of treatment weighted and multivariate adjusted Cox proportional hazard ratio; and TZD, thiazide diuretic.

Renin-Angiotensin System Inhibitors and COVID-19 be noninfected people. Randomized clinical trials of RAAS inhibition in people with established COVID-19 are ongoing, but these cannot shed light on the total effect on COVID-19. Several limitations must be considered when interpreting these data. The external validity of these findings to people on combination therapy with antihypertensive drugs, as well as to other geographic or ethnic contexts, is unknown. Given that people with preexisting cardiovascular and kidney diseases were excluded, whether these findings extend to those with underlying comorbidities is also unknown. However, exclusion of these patients was necessary to avoid collider bias and to isolate any interaction between RAAS inhibitors and COVID-19. Given that the definition for COVID-19 cases in this present study was based on admission to hospital or death (ie, a severity criterion), nonsevere cases of COVID-19 were not included in this study, meaning that the association between RAAS inhibition in primary prevention and a combination of the risk for infection and progression to severe disease was studied. However, severe COVID-19 cases are a good representation of (proportional to) all cases but are detected with much better precision because they are not subject to differences and biases in testing. Indeed, virus polymerase chain reaction testing strategies were constant in inpatient care, but changed substantially in outpatient care during follow-up, with unknown potential for bias. Furthermore, severe COVID-19 cases are more relevant considering that they are the burden to health care and that they reflect COVID-19 mortality risk in affected patients. Finally, it must be acknowledged that there was a low number of COVID-19related events (particularly for deaths with COVID-19) in this study's sample, which limits the power to detect weak associations in each outcome of interest.

The study has several advantages, including the availability of 2 million people using antihypertensive drugs, which allowed us to select the sample least prone to several biases. Additionally, we have complete coverage of all individuals in a society with universal access to health care with a negligible copayment, we have data on both in-hospital and outof-hospital mortality and could study the need for intensive care, and we used state-of-the-art methods for causal assumptions and development of biasminimized models.

The importance of the findings from this study are only emphasized by the way in which much of the world is currently struggling under the burden of subsequent waves of the COVID-19 pandemic, with infection and mortality rates far surpassing those seen during the initial wave during the first half of 2020. 132 Furthermore, there is now an urgent need for research that can properly inform and support healthcare systems by providing reliable information on associations of readily modifiable factors with COVID-19 outcomes.

In conclusion, despite potential limitations in the data, this study is among the best available evidence that the use of RAAS inhibitors in primary prevention does not increase the risk of severe COVID-19 outcomes; stronger data from which scientists and policy makers alike can base, with greater confidence, their current position on the safety of using RAAS inhibitors during the COVID-19 pandemic. A corresponding randomized clinical trial is unlikely to ever be executed. 

This research was supported by funding from the Swedish Heart-Lung Foundation and Anders Wiklöf.

None.

Data S1 Tables S1-S4 Figures Data S1.

The propensity score was estimated using gradient boosted classification and regression trees (CART) to determine the probability of being prescribed a RAAS inhibitor or not. Briefly, a CART partitions the feature space into disjoint regions and assigns a constant value in these regions. While highly interpretable, a single CART has poor predictive performance. With gradient boosting, several single trees are combined by sequentially adding CARTs to predict the (pseudo) residuals from the former CARTs, creating an ensemble with a superior predictive performance. 138 Indeed, gradient boosted CARTs have many desirable properties as they handle missing covariate values, interactions and nonlinear associations without the need for prior model specification. The influence of each additional CART is controlled via a shrinkage parameter and the optimal number of CARTs to include was determined by the average standardized mean differences (SMD) between the study groups. For each iteration, the SMD was calculated for every variable and averaged. The number of CARTs was then selected where the average SMD was minimized.

Recommendations were followed for tuning the hyperparameters, allowing for the assessment of up to four-way interactions with the shrinkage parameter set to 0.0005. 139 Each CART was fitted in a random subsample of 50% and 50,000 iterations were run. Unweighted and weighted characteristics of the study groups included in the secondary analysis, comprised of all Swedish residents using an angiotensin converting enzyme inhibitor in monotherapy, compared to those using a calcium channel blocker or thiazide diuretic in monotherapy; as of January 1 st 2020. ACE denotes angiotensin converting enzyme; ARB, angiotensin II type-I receptor blocker; CCB, calcium channel blocker; IQR, interquartile range; NSAID, nonsteroidal antiinflammatory drug; SEK, Swedish Kronor (currency of Sweden: 8.5 SEK = 1.0 USD); SMD, standardized mean difference; TZD, thiazide diuretic. Unweighted and weighted characteristics of the study groups included in the secondary analysis, comprised of all Swedish residents using an angiotensin II type-I receptor blocker in monotherapy, compared to those using a calcium channel blocker or thiazide diuretic in monotherapy; as of January 1 st 2020. ACE denotes angiotensin converting enzyme; ARB, angiotensin II type-I receptor blocker; CCB, calcium channel blocker; IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drug; SEK, Swedish Kronor (currency of Sweden: 8.5 SEK = 1.0 USD); SMD, standardized mean difference; TZD, thiazide diuretic. Swedish residents on antihypertensive monotherapy with RAAS inhibitor were compared to those on monotherapy with either a calcium channel blocker or thiazide diuretic, in both an intention to treat and an as treated model. In addition to assessing the associations of each RAAS inhibitor combined, the associations of ACE inhibitor and ARB use were also assessed independently of each other. RAAS denotes renin-angiotensin aldosterone system; CCB, calcium channel blocker; TZD, thiazide diuretic; HR, Cox proportional hazard ratio; CI, confidence interval; COVID-19, coronavirus disease 2019; ACE, angiotensin converting enzyme; ARB, angiotensin II type-I receptor blocker. Figure S1 . Causal assumptions.

The directed acyclic graphs approach used to identify the bias-minimized models investigating the total effects in this study. CCB denotes calcium channel blockers; COVID-19, coronavirus disease 2019; HOCM, hypertrophic obstructive cardiomyopathy; NSAIDs, non-steroidal anti-inflammatory drugs; PDE-5-inhibitors, phosphodiesterase type 5 inhibitors; RAAS, renin-angiotensin aldosterone system; TZD, thiazide diuretic. 

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensinconverting enzyme 2

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

The association of renin-angiotensin-aldosterone system inhibitors with outcomes among a predominantly ethnic minority patient population hospitalized with COVID-19: the Bronx experience

Angiotensin converting enzyme inhibitors, a risk factor of poor outcome in diabetic patients with COVID-19 infection

The Swedish Covid-19 intensive care cohort: risk factors of ICU admission and ICU mortality

COVID-19 in patients with CKD in New York City

angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience

The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: a retrospective, observational study in Northern Italy

Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with coronavirus disease 2019 severity and mortality

Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study

Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives

Clinical factors associated with progression and prolonged viral shedding in COVID-19 patients: a multicenter study

Risk factors for myocardial injury and death in patients with COVID-19: insights from a cohort study with chest computed tomography

Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality

Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

In-hospital mortality and use of renin-angiotensin system blockers in geriatrics patients

Positive association of angiotensin II receptor blockers, not angiotensinconverting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia

Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia

Therapy with agents acting on the renin-angiotensin system and risk of severe acute respiratory syndrome coronavirus 2 infection

Clinical, demographical characteristics and hospitalisation of 3,010 patients with Covid-19 in Friuli Venezia Giulia Region (Northern Italy). A multivariate, population-based, statistical analysis

Covid-19 team. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensinaldosterone system inhibitors

Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

Higher comorbidities and early death in hospitalized African-American patients with Covid-19

Association of angiotensin-converting enzyme inhibitors and angiotensin II blockers with severity of COVID-19: a multicenter, prospective study

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

Influence of inhibitors of the renin-angiotensin system on risk of acute respiratory distress syndrome in Danish hospitalized COVID-19 patients

Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension

Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States

Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients

Association of renin-angiotensinaldosterone system inhibitors with coronavirus disease 2019 (COVID-19)-related outcomes in Korea: a nationwide population-based cohort study

COVID-19: age, interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study

Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. a multi-centre observational study

Compliance of antihypertensive medication and risk of coronavirus disease 2019: a cohort study using big data from the Korean National Health Insurance Service

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study

The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea

Impact of antihypertensive agents on clinical course and in-hospital mortality: analysis of 169 hypertensive patients hospitalized for COVID-19

Clinical, regional, and genetic characteristics of Covid-19 patients from UK Biobank

Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensinreceptor blockers in France: results of the ACE-CoV study

Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment

Continued in-hospital angiotensinconverting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome

Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension

Association of reninangiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China

Association between renin-angiotensin system inhibitors and COVID-19 complications

Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study

Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: a hospital-based retrospective cohort study

Impact of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry

Reninangiotensin-aldosterone system blockers and the risk of Covid-19

Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection

Clinical characterization of patients with COVID-19 in primary care in catalonia: retrospective observational study

Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France

Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis

Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population

Impact of treatment with renin-angiotensin system inhibitors on clinical outcomes in hypertensive patients hospitalized with COVID-19

Northwell COVID-19 Research Consortium and the Northwell Nephrology

Outcomes of patients with end-stage kidney disease hospitalized with COVID-19

Underlying heart diseases and acute COVID-19 outcomes

Antecedent administration of angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists and survival after hospitalization for COVID-19 syndrome

Renin-angiotensin-aldosterone system blockers are not associated with coronavirus disease 2019 (COVID-19) hospitalization: study of 1,439 UK Biobank cases

Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China

Reninangiotensin-aldosterone system inhibitors and risk of Covid-19

Association of hypertension with all-cause mortality among hospitalized patients with COVID-19

Risk factors associated with in-hospital mortality in a US national sample of patients With COVID-19

Renin-angiotensin system inhibitors and mortality in patients with COVID-19

No association between use of angiotensinconverting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study

Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis

Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?

Antihypertensive drugs and COVID-19 risk: a cohort study of 2 million hypertensive patients

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19

Update on association between exposure to reninangiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea

Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients

Effects of angiotensin receptor blockers (ARBs) on in-hospital outcomes of patients with hypertension and confirmed or clinically suspected COVID-19

Association between renin-angiotensinaldosterone system inhibitors and COVID-19 infection in South Korea

High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy

Clinical impact of renin-angiotensin system inhibitors on inhospital mortality of patients with hypertension hospitalized for coronavirus disease 2019

ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19

Renin-angiotensinaldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43,000 patients

Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19

Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona

Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in Southern Catalonia

Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis

Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study

Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients

Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: a large casecontrol study

Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study

Comparative impacts of ACE (angiotensin-converting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality

Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors

A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19

Collider bias undermines our understanding of COVID-19 disease risk and severity

COVID-19 and the cardiovascular system

The public-private pendulum-patient choice and equity in Sweden

The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research

World Health Organization. International classification of disease and related health problems

Nordic Medico-Statistical Committee. NOMESCO classification of surgical procedures

World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology

2018 practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension

Johns Hopkins Coronavirus Resource Center. COVID-19 map

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis

R: A Language and Environment for Statistical Computing

Survival: Survival Analysis

twang: Toolkit for Weighting and Analysis of Nonequivalent Groups

Angiotensin-converting enzyme 2 protects from severe acute lung failure

The Elements of Statistical Learning: Data Mining, Inference, and Prediction

Propensity score estimation with boosted regression for evaluating causal effects in observational studies